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Abstract
Background and Objectives The aim of this study is to
investigate canagliflozin as an initial therapy in type 2
diabetes mellitus and to explore the effects on metabolic
parameters in relation to effects on glycemic control.
Subjects and Methods Treatment-naı¨ve subjects with type
2 diabetes mellitus received canagliflozin 50–100 mg/day
monotherapy. At 3 months, levels of glycemic and non-
glycemic parameters were compared with those at baseline
(n = 39). As a comparator, our previous data of baseline
glycosylated hemoglobin (HbA1c)-matched treatment-
naı¨ve subjects with ipragliflozin 25–50 mg monotherapy
(n = 27) were employed.
Results Significant reductions in HbA1c (from 9.96 to
8.33%), fasting blood glucose (-23.9%), homeostasis model
assessment-R (HOMA-R, -33.5%), body mass index
(-1.8%), and uric acid (UA, -5.2%) levels and significant
increases in homeostasis model assessment-B (HOMA-B,
30.1%) levels were observed. Approximately one third of the
subjects experienced certain adverse events. Similar results
were obtained with ipragliflozin. Baseline levels of HbA1c,
triglycerides, non-high-density lipoprotein-cholesterol
(HDL-C), and low-density lipoprotein-cholesterol (LDL-C)
were chosen as significant contributing factors for the changes
inHbA1c levelswith canagliflzoin, while only baseline HbA1c
levels were selected as such a factor with ipragliflozin. Sig-
nificant positive correlations between the changes in HbA1c
and changes innon-HDL-C (R = 0.3954) or between changes
inHbA1c and changes in LDL-C (R = 0.4317)were observed
with canagliflozin. With ipragliflozin, no such correlations
were noted. No correlations between the changes in HbA1c
and changes in body mass index were seen with both drugs.
Conclusions These results suggest that (1) canagliflozin
appears to offer clinically beneficial outcomes as an initial
therapy in subjects with type 2 diabetes mellitus, although
with certain adverse events. (2) Atherogenic cholesterols
including non-HDL-C and LDL-C could be involved in the
glycemic efficacy of canagliflozin. Thiswas not the casewith
ipragliflozin. (3) Unexpectedly, weight reductions with
canagliflozin are not associated with its glycemic efficacy.
Key Points
Canagliflozin as a first-line drug fpr patients with
type 2 diabetes mellitus appears to be beneficial in
many aspects including glycemic control, body
weight, uric acid (UA), insulin sensitivity, and beta-
cell function, though certain precautions are required
regarding its adverse events.
Atherogenic cholesterols including non-high-density
lipoprotein-cholesterol and low-density lipoprotein-
cholesterol may be involved in the glycemic efficacy
of canagliflozin.
Some differences may exist between canagliflozin
and ipragliflozin regarding their effect on metabolic
markers in relation to their glycemic efficacies.
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Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are
new glucose-lowering agents that exert their therapeutic
effects by inhibiting glucose reabsorption in the proximal
tubule of the kidneys [1–3]. This pharmacologically induced
glycosuria causes physiological and adaptive responses in
glucose homeostasis and other metabolic parameters. For
example, SGLT-2 inhibitors have also been shown to possess
some non-glycemic benefits such as weight reduction, blood
pressure control, diuretic action, and renal protection [4, 5].
Canagliflozin is one of the SGLT-2 inhibitors and is avail-
able in many countries including Japan, USA, and Europe
[6–8]. Similar glycemic and non-glycemic efficacies were
reported with other SGLT-2 inhibitors [6–8]. With the sim-
ple mechanism of discarding glucose into the urine, SGLT-2
inhibitors including canagliflozin were shown to ameliorate
beta-cell function and insulin resistance [1–3, 6–9]. How-
ever, consistent with their mechanisms of action, they are
associated with a higher incidence of certain adverse events
including genitalmycotic infections, urinary tract infections,
osmotic diuretic-related adverse events, and volume deple-
tion-related adverse events [10].
Metformin is regarded as the initial drug for patients
with type 2 diabetes mellitus (T2DM) in many countries
[11]. Sodium-glucose co-transporter 2 inhibitors including
canagliflozin are currently used as add-on therapy to met-
formin or other drugs as part of dual or triple therapy [11].
However, they could also be used as alternative first-line
options in patients with contraindications/intolerance to
metformin or in other situations [9, 12].
To date, limited clinical data are available on whether
canagliflozin could be used as an initial drug in patients
with T2DM in an actual clinical setting. This project was
initiated to investigate this question. It makes sense to
perform this type of study with drug-naı¨ve subjects using
monotherapy to eliminate the influences of other drugs as
much as possible. As an initial step towards investigating
this question, canaglflozin 50–100 mg/day monotherapy
was performed with drug-naı¨ve subjects with T2DM and
effects on some glycemic and non-glycemic parameters
were measured. As a comparator, our previous study per-
formed with ipragliflozin 25–50 mg/day monotherapy in
drug-naı¨ve subjects was employed [9].
2 Subjects and Methods
2.1 Subjects
Inclusion criteria were subjects who were newly diagnosed
with T2DM or who were previously diagnosed but were
untreated. The diagnosis was made according to the criteria
of the Japan Diabetes Society [13]. No subjects had
received any regularly prescribed drugs in the 6 months
prior to the study. Exclusion criteria were subjects with
clinically significant impaired renal function (creatinine
[1.5 mg/dL), hepatic function [glutamic oxaloacetic
transaminases/glutamic pyruvic transaminases (aspartate
transaminase and alanine transaminase) [70/70 IU/L],
history of heart disorders, severe hypertension (blood
pressure above 160/100 mmHg), type 1 diabetes mellitus,
and pregnancy. These subjects were recruited from the
outpatient department of the Division of Diabetes and
Endocrinology, Gyoda General Hospital (Saitama, Japan)
and other related hospitals. Initially, 53 subjects were
enrolled in this study. Nine subjects had stopped visiting
the hospitals without any reasons. Five subjects dropped
out because of tolerability problems and/or adverse events.
These drop-out subjects were excluded from data analysis.
Final analysis was performed with 39 subjects (fe-
male/male = 10/29); these patients received canagliflozin
50–100 mg/day monotherapy. Female subjects took 50
mg/day owing to frequent female adverse events (e.g.,
urogenital infections, ten), while male subjects took 100
mg/day. The subjects were encouraged to follow the
exercise and diet regimen suggested by the American
Diabetes Association [14]. The protocol was approved by
the Investigational Review Board of Gyoda General
Hospital, informed consent was obtained from the subjects
who participated, and the study was conducted in accor-
dance with principles of Good Clinical Practice. As a
control, our previous data from baseline HbA1c-matched
drug-naı¨ve subjects treated with ipragliflozin 25–50 mg
monotherapy were employed [9].
2.2 Laboratory Measurements
The primary endpoint was the changes in HbA1c levels
from baseline to 3 months. The HbA1c values are shown
with National Glycoprotein Standardization Program
standardization [15, 16] throughout this article. The sec-
ondary endpoints included fasting blood glucose (FBG),
insulin, body mass index (BMI), HOMA-R, HOMA-B,
triglycerides (TG), high-density lipoprotein-cholesterol
(HDL-C), non-HDL-C, and UA. Blood was collected at the
fasting state before breakfast and standard techniques were
used to measure these parameters as described previously
[9]. Measurements of HbA1c and FBG were performed
once a month. Insulin levels were measured at the start
(baseline) and at the end (3 months) of the study (Abbott
Japan, Tokyo, Japan). Anti-glutamic acid decarboxylase
antibody levels were measured in some suspected patients
to exclude those with type 1 diabetes mellitus (Mitsubishi
BML, Tokyo, Japan). HOMA-R and HOMA-B were
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calculated as described [17]; HOMA-R = insulin 9 FBG/
405, HOMA-B = insulin 9 360/(FBG-63). Hepatic [as-
partate transaminase (AST), alanine transaminase (ALT),
alkaline phosphatase (ALP), and gamma-glutamyl trans-
ferase (GGT)] and renal (blood urea nitrogen and crea-
tinine) functions were also monitored 1 month after
administration of canagliflozin. In the case of any signifi-
cant increases of these parameters, administration of
canagliflozin was to be discontinued. Responders of cana-
gliflozin were defined as reductions in HbA1c levels of
C1% [18].
2.3 Data Analyses
Change was calculated as the values at 3 months (post-
therapy) minus those at baseline (pre-therapy). When the
data were normally distributed, the paired Student’s t test
was used to analyze the changes in each group (intra-group
differences). When the data were not normally distributed,
the Wilcoxon signed-rank test was employed. The unpaired
Student’s t test was used to compare baseline values in
these two drug groups. Simple regression analysis was
performed to analyze the correlations of measured
parameters.
In an effort to identify any contributing factors for the
changes in HbA1c levels, multiple regression analysis was
performed using HbA1c as a dependent variable and other
glycemic and non-glycemic parameters including age,
HbA1c, FBG, insulin, BMI, HOMA-R, HOMA-B, TG,
HDL-C, non-HDL-C, and UA as independent variables.
The results were expressed as the mean plus standard
deviation. Throughout the statistical analysis, values of
p\ 0.05 were considered significant.
3 Results
3.1 Safety and Tolerability of Canagliflozin
Monotherapy as an Initial Therapy in Drug-
Naı¨ve Subjects with T2DM
Two out of 44 subjects reported a mild hypoglycemic
event, which could be easily managed by ingesting
glucose drinks. Ten subjects experienced pollakiuria and
three subjects reported skin rashes (eczema). Three
women complained of itching around the genital area
(potential genital mycotic infection and/or lower urinary
tract infection). Five subjects (two for pollakisuria and
three for potential urinary tract infections) discontinued
canagliflozin therapy because of intolerance or adverse
events. The final analysis was performed with 39 sub-
jects (29 for men and ten for women). These potential
adverse events occurred in the first 6 weeks of the ini-
tiation of the drug. Otherwise, no subjects had any
clinically significant elevations of renal or hepatic
enzymes. As for ipragliflozin, similar tolerability prob-
lems and adverse events were noted in our previous
study [9].
3.2 Effect of Canagliflozin Monotherapy
on Glycemic Parameters in Drug-Naı¨ve Subjects
with T2DM
Baseline characteristics of glycemic and non-glycemic
parameters were similar and no statistically significant
differences were observed between canagliflozin and
ipragliflozin subjects (results not shown, see baseline val-
ues of Table 1 and reference [9]). At 3 months, effective
Table 1 Changes in glycemic
and non-glycemic parameters
with 3 months’ treatment with
canagliflozin monotherapy in
drug-naı¨ve subjects with type 2
diabetes mellitus
Baseline 3 months p values % changes
Age 53.1 ± 14.0
F/M 10/29
HbA1c (%) 9.96 ± 2.52 8.33 ± 1.66 \0.00001 -16.3
FBG (mg/dL) 193.4 ± 66.7 147.1 ± 32.4 \0.00001 -23.9
Insulin (lU/mL) 9.45 ± 7.17 8.42 ± 6.26 0.077 -10.8
HOMA-R 4.50 ± 9.15 2.99 ± 2.17 \0.00001 -33.5
HOMA-B 31.91 ± 30.12 41.52 ± 38.20 \0.03 30.1
BMI 26.84 ± 5.56 26.34 ± 5.50 \0.00001 -1.8
UA (mg/dL) 5.35 ± 1.21 5.07 ± 1.19 \0.05 -5.2
T-C (mg/dL) 219.1 ± 38.7 215.1 ± 39.1 n.s. -1.8
TG (mg/dL) 187.2 ± 134.8 165.6 ± 95.8 0.057 -11.5
HDL-C (mg/dL) 52.4 ± 13.3 54.4 ± 12.2 n.s. 3.8
Non-HDL-C (mg/dL) 166.6 ± 38.3 160.7 ± 39.6 n.s. -3.5
LDL-C (mg/dL) 140.2 ± 37.8 137.1 ± 34.6 n.s. -2.2
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significant reductions in FBG and HbA1c levels were
observed with canagliflozin 50–100 mg monotherapy (for
each value and statistical significance, see Table 1). Sig-
nificant negative correlations were observed between the
changes in HbA1c and baseline HbA1c levels (Fig. 1).
Seventeen out of 39 subjects were non-responders whose
HbA1c levels had\1% reductions from baseline [18]. Nine
out of 39 subjects achieved HbA1c \7% in 3 months’
treatment with canagliflozin (results not shown). Similar
results regarding the glycemic efficacy were obtained with
ipragliflozin in our previous study [9]. Multiple regression
analysis was performed to identify potential contributing
factors for the changes (reductions) in HbA1c levels with
canagligliflozin or ipragliflozin as described in Sect. 2.
Among the parameters tested, baseline levels of HbA1c,
TG, non-HDL-C, and LDL-C were selected as the signif-
icant contributing factors for the changes in HbA1c levels
(Table 2A). As for ipragliflozin, only baseline levels of
HbA1c were selected as such a factor (Table 2B). To assess
the effect of canagliflozin on insulin resistance and beta-
cell function, changes in HOMA-R and HOMA-B levels
were evaluated. At 3 months, significant reductions in
HOMA-R levels and increases in HOMA-B levels were
observed (Table 1). Similar results were obtained with
ipragliflozin [9].
3.3 Effect of Canagliflozin on Non-Glycemic
Parameters in Drug-Naı¨ve Subjects with T2DM
Effects of canagliflozin on non-glycemic parameters
including body weight, lipids, and serum UA were inves-
tigated. Among the parameters tested, significant reduc-
tions in BMI and serum UA levels were seen (Table 1). No
significant changes were noted in lipid levels, though TG
levels had a tendency to decrease (Table 1). Blood pressure
was also monitored. Reduced levels of blood pressure were
observed with canagliflozin; however, the variations were
so large and therefore no solid data were established
regarding the effect of canagliflozin on blood pressure
(results not shown). Similar results were obtained with
ipragliflozin [9].
3.4 Link Between the Changes in Metabolic
Parameters
As shown in Table 2A, baseline levels of TG, non-HDL-C,
and LDL-C were chosen as significant contributing factors
for the changes in HbA1c levels with canagliflozin. How-
ever, only baseline HbA1c levels were selected as such a
factor with ipragliflozin (Table 2B). Simple regression
analysis was performed to identify any correlations
between the changes in HbA1c and those of glycemic and
non-glycemic parameters with canagliflozin or ipragli-
flozin. As shown in Table 3A, significant positive corre-
lations between HbA1c and non-HDL-C or between HbA1c
and LDL-C were observed with canagliflozin. By contrast,
with ipragliflozin, significant positive correlations between
HbA1c and TG and negative correlations between HbA1c
and UA were seen (Table 3B). With both drugs, significant
positive correlations between HbA1c and FBG and negative
correlations between HbA1c and insulin or between HbA1c
and HOMA-B were observed (Table 3A and B). Unex-
pectedly, no correlations were noted between the changes
of BMI and those of glycemic parameters (Table 3A and
B).
4 Discussion
4.1 Glycemic Efficacy and Safety of Canagliflozin
as an Initial Therapy with T2DM
Canagliflozin monotherapy as an initial option in drug-
naı¨ve subjects with T2DM was shown to be rather effective
and to have beneficial effects on beta-cell function, insulin
sensitivity, and body weight (Table 1). Our group has been
y = -0.5633x + 3.982 
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hemoglobin (HbA1c) levels of
canagliflozin. Simple regression
analysis was performed between
baseline HbA1c and changes (D)
in HbA1c levels
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studying the effect of oral hypoglycemic drugs in drug-
naı¨ve subjects with T2DM in the past years. The glycemic
efficacy of canagliflozin is comparable to other drugs
including ipragliflozin [9], pioglitazone [19], alogliptin
[20], or teneligliptin [21]. However, certain proportions of
the drug-naı¨ve subjects with T2DM were non-responders to
canagliflozin (17 out of 39 subjects, reductions in HbA1c of
\1%). Currently, we are investigating whether any dif-
ferences exist in metabolic parameters between responders
and non-responders treated with canagliflozin monother-
apy. Analogous to other oral hypoglycemic drugs (e.g.,
another SGLT-2 inhibitor ipragliflozin) [9], the glycemic
efficacy of canagliflozin is baseline HbA1c dependent
(Fig. 1).
Further, it was shown that the glycemic efficacies of
canagliflozin were linked to improved beta-cell function,
but not to decreased insulin resistance (Table 3A). It
remains to be investigated whether the above observations
also occur in subjects treated with multiple drugs or insu-
lin. There are at least six SGLT-2 inhibitors on the market.
It is of interest to investigate whether any differences exist
in glycemic and non-glycemic efficacies among these dif-
ferent SGLT-2 inhibitors. Because canagliflozin is widely
marketed worldwide, efficacy across different ethnicities
will be of great interest.
Multiple regression analysis revealed that baseline
levels of HbA1c, and atherogenic lipids including TG, non-
HDL-C, and LDL-C were selected as the significant con-
founding factors for the changes in the glycemic efficacy of
canagliflozin (Table 2A). However, only baseline HbA1c
levels were selected as such a factor with ipragliflozin
(Table 2B). Although canagliflozin appears to have no
effect on these atherogenic lipids in subjects overall
(Table 1A), changes in HbA1c levels had significant
Table 2 Multiple regression
analysis with the factors




0 Coefficient SE t value p value R2
(A) Canagliflozin
Constant -1.374 3.7421 -0.36717 0.71658 0
Age 0.024168 0.018375 1.3152 2.00E-01 0.024128
HbA1c -0.83641 0.18562 -4.506 0.000134 0.46652
FBG 0.017085 0.009091 1.8794 0.071895 0.20613
Insulin 0.047408 0.29753 0.15934 0.87468 0.053026
BMI 0.028767 0.072687 0.39576 0.69564 0.020409
HOMA-R -0.02944 0.45409 -0.06483 0.94882 0.00085
HOMA-B 0.005526 0.033547 0.16473 0.87048 0.15989
TG -0.00905 0.003648 -2.4803 0.020214 0.006131
HDL-C 0.022281 0.018685 1.1925 0.24427 0.023862
Non-HDL-C 0.058565 0.02184 2.6815 0.012794 0.00772
LDL-C -0.05288 0.021241 -2.4895 0.019805 9.82E-05
UA 0.063483 0.22951 0.2766 0.78436 0.01183
(B) Ipragliflozin
Constant 5.0469 4.2932 1.1756 0.25509 0
Age 0.019515 0.022548 0.86548 0.39816 0.15101
HbA1c -0.48812 0.23057 -2.117 0.048445 0.43358
FBG -0.01283 0.009475 -1.3542 0.19243 0.20424
Insulin -0.21354 0.35315 -0.60469 0.55293 0.011142
BMI -0.09143 0.06348 -1.4403 0.16696 0.066983
HOMA-R 0.77484 0.58649 1.3212 0.203 0.010184
HOMA-B -0.01357 0.03741 -0.36264 0.7211 0.089243
TG -0.00114 0.002732 -0.4171 0.68154 0.091779
HDL-C 0.002301 0.023205 0.099156 0.92211 0.050386
Non-HDL-C 0.005596 0.01869 0.2994 0.76807 0.16314
LDL-C -0.0071 0.018719 -0.3794 0.70883 0.028367
UA 0.19859 0.22846 0.86926 0.39615 0.070164
Dependent variables: changes (D) in HbA1c levels, independent variables: age, baseline levels of HbA1c,
fasting blood glucose (FBG), insulin, body mass index (BMI), homeostasis model assessment-R (HOMA-
R), homeostasis model assessment-B (HOMA-B), triglycerides (TG), high-density lipoprotein-cholesterol
(HDL-C), non-HDL-C, and uric acid (UA)
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correlations with those with atherogenic cholesterols
including non-HDL-C and LDL-C (Table 3A). The
underlying mechanism responsible for this phenomenon
remains to be investigated. One potential explanation is
that glucose lowering per se with canagliflozin is associ-
ated with a reduced influx of glucose to the liver and
reduced very low-density lipoprotein/apoliprotein E pro-
duction, thereby causing reductions in atherogenic lipids.
In fact, we are currently working on responders and non-
responders with canagliflozin. Indeed, atherogenic choles-
terols including non-HDL-C and LDL-C were differen-
tially regulated between these two groups (more reductions
were observed in responders vs. non-responders; E. Kutoh,
personal communication). However, ipragliflozin had dif-
ferent profiles. Significant positive correlations between
HbA1c and TG and negative correlations between HbA1c
and UA were seen with ipragliflozin (Table 3B). These
results imply that these two drugs differ in the effects on
metabolic parameters in relation to their glycemic effica-
cies. It is also possible that the differences in lipid regu-
lation with these two drugs were a result of the distinct
backgrounds of the subjects between these two groups.
Safety and tolerability could be of concern. Five out of
44 subjects discontinued therapy because of intolerance or
adverse events. Potential canagliflozin-induced adverse
events occurred in approximately one third of subjects
(e.g., pollakiuria, genital and/or lower urinary tract infec-
tion). Although no robust statistical analysis has been
performed, rates of adverse events, intolerance, or dis-
continuation with canagliflozin appear to be higher than
other drugs but similar to ipragliflozin [9]. The duration of
this study is only 3 months with relatively young subjects.
A long-term follow-up of safety issues in elderly patients is
required to have a better understanding of the safety pro-
files of canagliflozin.
4.2 Non-Glycemic Efficacy of Ipragiflozin
One of the most notable non-glycemic efficacies of cana-
gliflozin is the reduction in body weight (Table 1). This is
similar to other SGLT-2 inhibitors [1–3, 9]. Many diabetes
drugs such as insulin, sulfonylureas, and thiazolidinediones
cause weight gain. Therefore, drugs that have reducing
effects on body weight are particularly important. To date,
few studies report the relationship between body weight
reductions with canagliflozin and its effects on glycemic
control. Our investigation on this issue unexpectedly
revealed that the glycemic efficacies of canagliflozin were
not associated with the degrees of body weight reductions
(Table 3A). Recently, we reported two distinct glucose-
lowering mechanisms may exist depending on body weight
changes with ipragliflozin [22]. Currently, we are investi-
gating whether similar results would be obtained with
canagliflozin.
Significant reductions in serum UA levels were
observed (Table 1). This is most probably owing to the
increased UA levels in the urine, possibly through the urate
transporter [23]. However, a possibility that canagliflozin
reduces hepatic UA productions cannot be ruled out. Ele-
vated UA levels are a risk factor for cardiovascular disor-
der as well as gout [24]. No significant effects on lipid
parameters were noted with canagliflozin in overall sub-
jects, though TG levels had a tendency to decrease
(Table 1). Effects on lipid metabolism with SGLT-2 inhi-
bitors in general are inconsistent and non-significant [1–3].
Sodium-glucose co-transporter 2 inhibitors were shown to
reduce blood pressure, probably as a result of weight loss
and diuretic action [4, 5]. Sodium-glucose co-transporter 2
inhibitors induce beneficial changes in these above-men-
tioned cardiovascular risk factors in addition to improved
glycemic control. It was recently reported that empagli-
flozin had favorable cardiovascular outcomes in patients
with T2DM at high risk for cardiovascular events [25]. As
shown in this work, canagliflozin appears to have favorable
metabolic profiles (e.g., reducing UA or body weight) other
Table 3 Correlations between the changes in glycosylated hemo-
globin (DHbA1c) and those of other parameters
R p values
(A) Canagliflozin
DHbA1c vs. DFBG 0.7443 \0.00001
vs. Dinsulin -0.3888 \0.002
vs. DBMI 0.2402 n.s.
vs. DHOMA-R 0.0665 n.s.
vs. DHOMA-B -0.6328 \0.00001
vs. DTG 0.0982 n.s.
vs. DHDL-C -0.1198 n.s.
vs. Dnon-HDL-C 0.3954 \0.002
vs. DLDL-C 0.4317 \0.01
vs. DUA -0.227 n.s.
(B) Ipragliflozin
DHbA1c vs. DFBG 0.5524 \0.001
vs. Dinsulin -0.4864 \0.005
vs. DBMI 0.1836 n.s.
vs. DHOMA-R -0.0342 n.s.
vs. DHOMA-B -0.5813 \0.0005
vs. DTG 0.3978 \0.05
vs. DHDL-C -0.1665 n.s.
vs. Dnon-HDL-C 0.1723 n.s.
vs. DLDL-C -0.1091 n.s.
vs. DUA -0.4309 \0.02
Simple regression analysis was performed between the changes of
indicated parameters
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than its glycemic efficacy, although it remains to be
investigated whether canagliflozin has similar outcomes on
cardiovascular events. Results from large clinical studies of
SGLT-2 inhibitors including canagliflozin (CANVAS,
[26]) will answer this question.
4.3 Limitations and Strengths of the Study
There are a number of limitations with this study. It is an
observational (though prospective) study with small num-
bers of subjects and a short study duration. Further, male
subjects took 100 mg/day while female subjects received
50 mg/day; this can result in an inaccurate evaluation of the
efficacy of a drug efficacy. However, one can assume that
the observed changes were caused exclusively by cana-
gliflozin based on the design of the study (monotherapy
with drug-naı¨ve patients). Further randomized double-blind
placebo-controlled studies of longer duration and with an
increased number of subjects are required to strengthen the
findings of this study.
5 Conclusions
The results of this study add the following novel infor-
mation to our current knowledge. [1] Canagliflozin is a
candidate for one of the first-line drugs in patients with
T2DM. It has beneficial effects on some parameters
including UA, body weight, insulin sensitivity, and beta-
cell function, though certain precautions are required
regarding its tolerability and adverse events. [2] Athero-
genic cholesterols including non-HDL-C and LDL-C
appear to be involved in the glycemic efficacy of cana-
gliflozin, while TG and UA could be selected as such
factors with ipragliflozin. Thus, these two drugs may differ
in their effects on metabolic markers in relation to their
glycemic efficacies. It remains to be investigated whether
other SGLT-2 inhibitors (e.g., dapagliflozin, empagliflozin)
have similar or distinct regulatory patters.
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